Vet Med - Czech, 2023, 68(12):477-482 | DOI: 10.17221/90/2023-VETMED

Canine oral melanoma with suspected pulmonary metastasis: Combination of immunotherapy and tyrosine kinase inhibitor treatmentCase Report

KR Kim1,2, DH Kim1,2, MJ Jung1,2, DM Sihn1,3, SW Jeong1,3, JH Kim1,2
1 KU Animal Cancer Center, Konkuk University Veterinary Medical Teaching Hospital, Seoul, Republic of Korea
2 Department of Veterinary Internal Medicine, College of Veterinary Medicine, Konkuk University, Seoul, Republic of Korea
3 Department of Veterinary Surgery, College of Veterinary Medicine, Konkuk University, Seoul, Republic of Korea

This case report follows a 10-year-old castrated male Miniature Schnauzer dog presented with a history of incomplete surgical resection of an oral malignant melanoma (amelanotic type) on the right mandible. Melanoma vaccine therapy was administered due to incomplete surgical resection, however, new masses were detected on the contralateral mandible and suspected pulmonary metastasis occurred at 2 weeks and 7 months, respectively, following the first melanoma vaccination. At the time of detecting the pulmonary metastasis, targeted chemotherapy was initiated with the owner’s consent using imatinib (10 mg/kg/day, p.o.), a tyrosine kinase inhibitor (TKI). The patient did not show any significant adverse events related to both anticancer treatments. Three months following the first dose of imatinib, the absence of the suspected pulmonary metastatic nodules on radiography indicated complete remission. In conclusion, this report describes the achievement of clinical remission of suspected pulmonary metastatic oral malignant melanoma and an extension of survival time in a dog given a combination treatment of immunotherapy and tyrosine kinase inhibitor.

Keywords: dog; imatinib; malignant melanoma

Received: September 7, 2023; Revised: October 24, 2023; Accepted: November 6, 2023; Prepublished online: December 26, 2023; Published: December 29, 2023  Show citation

ACS AIP APA ASA Harvard Chicago IEEE ISO690 MLA NLM Turabian Vancouver
Kim K, Kim D, Jung M, Sihn D, Jeong S, Kim J. Canine oral melanoma with suspected pulmonary metastasis: Combination of immunotherapy and tyrosine kinase inhibitor treatment. CAAS Agricultural Journals. 2023;68(12):477-482. doi: 10.17221/90/2023-VETMED.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ahn R, Ursini-Siegel J. Clinical potential of kinase inhibitors in combination with immune checkpoint inhibitors for the treatment of solid tumors. Int J Mol Sci. 2021 Mar 5;22(5):2608. Go to original source... Go to PubMed...
    2. Aris M, Barrio MM. Combining immunotherapy with oncogene-targeted therapy: A new road for melanoma treatment. Front Immunol. 2015 Feb 9;6:46. Go to original source... Go to PubMed...
    3. Bergman PJ. Canine oral melanoma. Clin Tech Small Anim Pract. 2007 May;22(2):55-60. Go to original source... Go to PubMed...
    4. Berry A, Hayes A, Schiavo L, Dobson J. Multimodal treatment of a canine lingual melanoma using a combination of immunotherapy and a tyrosine kinase inhibitors. Vet Sci. 2022 Jan 29;9(2):54. Go to original source... Go to PubMed...
    5. Bonkobara M. Dysregulation of tyrosine kinases and use of imatinib in small animal practice. Vet J. 2015 Aug;205(2):180-8. Go to original source... Go to PubMed...
    6. Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, Panageas KS, Busam KJ, Chmielowski B, Lutzky J, Pavlick AC, Fusco A, Cane L, Takebe N, Vemula S, Bouvier N, Bastian BC, Schwartz GK. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011 Jun 8;305(22):2327-34. Go to original source... Go to PubMed...
    7. Chu PY, Pan SL, Liu CH, Lee J, Yeh LS, Liao AT. KIT gene exon 11 mutations in canine malignant melanoma. Vet J. 2013 May;196(2):226-30. Go to original source... Go to PubMed...
    8. Dank G, Rassnick KM, Sokolovsky Y, Garrett LD, Post GS, Kitchell BE, Sellon RK, Kleiter M, Northrup N, Segev G. Use of adjuvant carboplatin for treatment of dogs with oral malignant melanoma following surgical excision. Vet Comp Oncol. 2014 Mar;12(1):78-84. Go to original source... Go to PubMed...
    9. Deinlein T, Wolf IH, Rainer B, Kupsa R, Richtig E, Hofmann-Wellenhof R, Zalaudek I. Treatment of primary and metastatic multifocal mucosal melanoma of the oral cavity with imatinib. Case Rep Oncol. 2017 Jun 22;10(2):558-63. Go to original source... Go to PubMed...
    10. Gramer I, Kessler M, Geyer J. Detection of novel polymorphisms in the ckit gene of canine patients with lymphoma, melanoma, haemangiosarcoma, and osteosarcoma. Vet Res Commun. 2016 Jun;40(2):89-95. Go to original source... Go to PubMed...
    11. Iussich S, Maniscalco L, Di Sciuva A, Iotti B, Morello E, Martano M, Gattino F, Buracco P, De Maria R. PDGFRs expression in dogs affected by malignant oral melanomas: Correlation with prognosis. Vet Comp Oncol. 2017 Jun;15(2):462-9. Go to original source... Go to PubMed...
    12. Kawabe M, Mori T, Ito Y, Murakami M, Sakai H, Yanai T, Maruo K. Outcomes of dogs undergoing radiotherapy for treatment of oral malignant melanoma: 111 cases (2006-2012). J Am Vet Med Assoc. 2015 Nov 15;247(10):1146-53. Go to original source... Go to PubMed...
    13. Lachowicz JL, Post GS, Brodsky E. A phase I clinical trial evaluating imatinib mesylate (Gleevec) in tumor-bearing cats. J Vet Intern Med. 2005 Nov-Dec;19(6):860-4. Go to original source...
    14. Massicotte MH, Brassard M, Claude-Desroches M, Borget I, Bonichon F, Giraudet AL, Do Cao C, Chougnet CN, Leboulleux S, Baudin E, Schlumberger M, de la Fouchardiere C. Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: A retrospective study of the TUTHYREF network. Eur J Endocrinol. 2014 Mar 8;170(4):575-82. Go to original source... Go to PubMed...
    15. Pellin MA. The use of oncept melanoma vaccine in veterinary patients: A review of the literature. Vet Sci. 2022 Oct 28;9(11):597. Go to original source... Go to PubMed...
    16. Proulx DR, Ruslander DM, Dodge RK, Hauck ML, Williams LE, Horn B, Price GS, Thrall DE. A retrospective analysis of 140 dogs with oral melanoma treated with external beam radiation. Vet Radiol Ultrasound. 2003 May-Jun;44(3):352-9. Go to original source... Go to PubMed...
    17. Rosenberg A, Mathew P. Imatinib and prostate cancer: Lessons learned from targeting the platelet-derived growth factor receptor. Expert Opin Investig Drugs. 2013 Jun;22(6):787-94. Go to original source... Go to PubMed...
    18. Sacha T. Imatinib in chronic myeloid leukemia: An overview. Mediterr J Hematol Infect Dis. 2014 Jan 2;6(1):e2014007. Go to original source... Go to PubMed...
    19. Saito Y, Sugino K, Takami H, Matsuzu K, Uruno T, Ohkuwa K, Kitagawa W, Nagahama M, Kawakubo H, Ito K, Kitagawa Y. Clinical status and treatment of liver metastasis of differentiated thyroid cancer using tyrosine kinase inhibitors. World J Surg. 2018 Nov;42(11):3632-7. Go to original source... Go to PubMed...
    20. Smedley RC, Thaiwong T, Deeth LE, Kiupel M. Correlation between KIT expression and c-Kit mutations in 2 subtypes of canine oral melanocytic neoplasms. Vet Pathol. 2021 Jul;58(4):683-91. Go to original source... Go to PubMed...
    21. Thomas A, Rajan A, Giaccone G. Tyrosine kinase inhibitors in lung cancer. Hematol Oncol Clin North Am. 2012 Mar;26(3):589-605. Go to original source... Go to PubMed...
    22. Treggiari E, Grant JP, North SM. A retrospective review of outcome and survival following surgery and adjuvant xenogeneic DNA vaccination in 32 dogs with oral malignant melanoma. J Vet Med Sci. 2016 Jun 1;78(5):845-50. Go to original source... Go to PubMed...
    23. Verganti S, Berlato D, Blackwood L, Amores-Fuster I, Polton GA, Elders R, Doyle R, Taylor A, Murphy S. Use of Oncept melanoma vaccine in 69 canine oral malignant melanomas in the UK. J Small Anim Pract. 2017 Jan;58(1):10-6. Go to original source... Go to PubMed...
    24. Wilmott JS, Scolyer RA, Long GV, Hersey P. Combined targeted therapy and immunotherapy in the treatment of advanced melanoma. Oncoimmunology. 2012 Sep 1;1(6):997-9. Go to original source... Go to PubMed...
    25. Yang Z, Tam KY. Combination strategies using EGFR-TKi in NSCLC therapy: Learning from the gap between pre-clinical results and clinical outcomes. Int J Biol Sci. 2018 Feb 5;14(2):204-16. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content